PMID- 38034713
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231202
IS  - 2405-8440 (Print)
IS  - 2405-8440 (Electronic)
IS  - 2405-8440 (Linking)
VI  - 9
IP  - 11
DP  - 2023 Nov
TI  - Vesicular monoamine transporter (VMAT) regional expression and roles in 
      pathological conditions.
PG  - e22413
LID - 10.1016/j.heliyon.2023.e22413 [doi]
LID - e22413
AB  - Vesicular monoamine transporters (VMATs) are key regulators of neurotransmitter 
      release responsible for controlling numerous physiological, cognitive, emotional, 
      and behavioral functions. They represent important therapeutic targets for 
      numerous pathological conditions. There are two isoforms of VMAT transporter 
      proteins that function as secondary active transporters into the vesicle for 
      storage and release via exocytosis: VMAT1 (SLC18A1) and VMAT2 (SLC18A2) which 
      differ in their function, quantity, and regional expression. VMAT2 has gained 
      considerable interest as a therapeutic target and diagnostic marker. Inhibitors 
      of VMAT2 have been used as an effective therapy for a range of pathological 
      conditions. Additionally, the functionality and phenotypic classification of 
      classical and nonclassical catecholaminergic neurons are identified by the 
      presence of VMAT2 in catecholaminergic neurons. Dysregulation of VMAT2 is also 
      implicated in many neuropsychiatric diseases. Despite the complex role of VMAT2, 
      many aspects of its function remain unclear. Therefore, our aim is to expand our 
      knowledge of the role of VMAT with a special focus on VMAT2 in different systems 
      and cellular pathways which may potentially facilitate development of novel, more 
      specific therapeutic targets. The current review provides a summary demonstrating 
      the mechanism of action of VMAT, its functional role, and its contribution to 
      disease progression and utilization as therapeutic targets.
CI  - (c) 2023 The Authors.
FAU - Alwindi, Malik
AU  - Alwindi M
AD  - St George's University Hospital, London SW17 0QT, United Kingdom.
FAU - Bizanti, Ariege
AU  - Bizanti A
AD  - Burnett School of Biomedical Sciences, College of Medicine, University of Central 
      Florida, Orlando, FL 32816, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231115
PL  - England
TA  - Heliyon
JT  - Heliyon
JID - 101672560
PMC - PMC10687066
OTO - NOTNLM
OT  - Brain
OT  - Catecholamine
OT  - Dopamine
OT  - Norepinephrine
OT  - Vesicular monoamine transporter
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/11/30 18:45
MHDA- 2023/11/30 18:46
PMCR- 2023/11/15
CRDT- 2023/11/30 17:37
PHST- 2022/11/14 00:00 [received]
PHST- 2023/09/28 00:00 [revised]
PHST- 2023/11/10 00:00 [accepted]
PHST- 2023/11/30 18:46 [medline]
PHST- 2023/11/30 18:45 [pubmed]
PHST- 2023/11/30 17:37 [entrez]
PHST- 2023/11/15 00:00 [pmc-release]
AID - S2405-8440(23)09621-4 [pii]
AID - e22413 [pii]
AID - 10.1016/j.heliyon.2023.e22413 [doi]
PST - epublish
SO  - Heliyon. 2023 Nov 15;9(11):e22413. doi: 10.1016/j.heliyon.2023.e22413. 
      eCollection 2023 Nov.